NCT06043011 Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
| NCT ID | NCT06043011 |
| Status | Recruiting |
| Phase | — |
| Sponsor | iOMEDICO AG |
| Condition | Chronic Lymphocytic Leukemia (CLL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,950 participants |
| Start Date | 2023-09-27 |
| Primary Completion | 2033-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,950 participants in total. It began in 2023-09-27 with a primary completion date of 2033-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of the respective NHL * If patient is alive: signed written informed consent * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment. * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment. Exclusion Criteria: * No systemic therapy for respective lymphoid malignancy.
Contact & Investigator
Rainer Claus, Prof. Dr.
STUDY CHAIR
Universitätsklinikum Augsburg, Germany
Frequently Asked Questions
Who can join the NCT06043011 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Lymphocytic Leukemia (CLL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06043011 currently recruiting?
Yes, NCT06043011 is actively recruiting participants. Contact the research team at rubin@iomedico.com for enrollment information.
Where is the NCT06043011 trial being conducted?
This trial is being conducted at Freiburg im Breisgau, Germany.
Who is sponsoring the NCT06043011 clinical trial?
NCT06043011 is sponsored by iOMEDICO AG. The principal investigator is Rainer Claus, Prof. Dr. at Universitätsklinikum Augsburg, Germany. The trial plans to enroll 2,950 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.